Relay Therapeutics made a smart bet on a real insight: proteins move, and understanding that motion reveals drug targets nobody else can see. Their FGFR2 inhibitor showed genuine clinical promise in bile duct cancer patients who had run out of options. But small biotech is brutal economics. They burn over $300 million per year. The science is compelling. The balance sheet demands results fast.
Founded
2016
HQ
Cambridge, Massachusetts, USA
Total Raised
~$1.4B
Founder
David E. Shaw, Matthew Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy
Status
Public (NASDAQ: RLAY)
Website
www.relaytx.comTHE ORIGIN STORY
Relay was founded in 2016 by a team that bridged Harvard medicinal chemistry and D.E. Shaw Research's world-class molecular dynamics simulation work.
The key insight was that traditional drug design treated proteins as static 3D structures — but proteins constantly move, and those movements reveal binding pockets invisible in standard crystallography. Matthew Shair brought the chemistry expertise.
The computational biology came from D.E. Shaw's deep molecular simulation capability, which had spent a decade mapping protein motion at atomic scale.
WHAT THEY ACTUALLY DO
Drug discovery and development. Relay uses its protein motion analysis platform to identify drug targets that static structure-based tools miss, designs small molecule drugs against those targets, runs clinical trials, and aims to commercialize or partner successful candidates with large pharmaceutical companies.
THE PRODUCTS
RLY-4008 (FGFR2 inhibitor for FGFR2-altered cholangiocarcinoma, bile duct cancer), protein motion analysis platform (Dynamo)
HOW THEY GREW
Generate early clinical proof of concept with platform-validated drug candidates. Use Phase 2 data to attract large pharma partnership deals or co-development agreements.
The 2020 IPO funded the expensive clinical-stage work that would have been impossible to finance privately.
THE HARD PART
Cash burn and clinical timeline pressure. Running oncology trials in small patient populations costs hundreds of millions and takes years.
The biotech funding market contracted sharply after 2021. Relay needs a significant clinical win or a major partnership before the runway becomes the headline.
MONEY TRAIL
Series B
2018 · Led by GV
$63M raised
Series C
2020 · Led by Redmile Group
$400M raised
IPO
2020 · Led by Public Markets (NASDAQ: RLAY)
$400M raised
WHO BACKED THEM
GV (Google Ventures), Redmile Group, Third Rock Ventures, Atlas Venture, Casdin Capital
Related Profiles
Companies
Chai Discovery
Both companies use cutting-edge computational biology to find drug targets. Chai Discovery focuses on protein structure prediction as a platform. Relay focuses on protein motion to reveal hidden binding sites.
Recursion Pharmaceuticals
Fellow publicly traded biotech companies betting that computational methods can transform drug discovery timelines and costs. Both are burning significant capital to prove the platform thesis before the market loses patience.
Head-to-Head
Compare Relay Therapeutics vs another company.